KBC Group NV Grows Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

KBC Group NV raised its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 41.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 192,479 shares of the medical device company's stock after buying an additional 56,461 shares during the period. KBC Group NV owned about 0.29% of Tandem Diabetes Care worth $6,933,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Bellevue Group AG grew its holdings in shares of Tandem Diabetes Care by 19.9% during the 3rd quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company's stock valued at $78,496,000 after purchasing an additional 307,624 shares during the last quarter. MetLife Investment Management LLC grew its holdings in shares of Tandem Diabetes Care by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 37,422 shares of the medical device company's stock valued at $1,587,000 after purchasing an additional 21,086 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Tandem Diabetes Care by 134.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company's stock valued at $8,379,000 after purchasing an additional 113,355 shares during the last quarter. Oppenheimer & Co. Inc. grew its holdings in shares of Tandem Diabetes Care by 368.5% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 26,125 shares of the medical device company's stock valued at $1,108,000 after purchasing an additional 20,549 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Tandem Diabetes Care by 32.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 272,097 shares of the medical device company's stock worth $11,540,000 after acquiring an additional 66,687 shares during the last quarter.

Tandem Diabetes Care Stock Down 1.8 %

NASDAQ:TNDM traded down $0.66 on Monday, reaching $36.40. 776,067 shares of the stock traded hands, compared to its average volume of 919,695. The company has a market capitalization of $2.39 billion, a price-to-earnings ratio of -18.86 and a beta of 1.32. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 12 month low of $21.94 and a 12 month high of $53.69. The company's fifty day simple moving average is $34.85 and its 200 day simple moving average is $37.37.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The firm had revenue of $243.97 million during the quarter, compared to analyst estimates of $224.14 million. During the same period in the previous year, the business posted ($0.38) earnings per share. The business's revenue for the quarter was up 31.4% on a year-over-year basis. Equities analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Insider Transactions at Tandem Diabetes Care

In related news, Director Kim D. Blickenstaff sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the completion of the sale, the director now directly owns 195,190 shares in the company, valued at approximately $5,855,700. The trade was a 4.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 2.20% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on TNDM. Sanford C. Bernstein began coverage on shares of Tandem Diabetes Care in a report on Wednesday, November 6th. They issued an "outperform" rating and a $42.00 price target on the stock. Canaccord Genuity Group cut their price target on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Robert W. Baird cut their price target on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a "neutral" rating on the stock in a report on Thursday, November 7th. Citigroup cut their price target on shares of Tandem Diabetes Care from $57.00 to $50.00 and set a "buy" rating on the stock in a report on Wednesday, December 11th. Finally, Barclays raised their price target on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an "overweight" rating in a report on Friday, November 8th. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $53.81.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.